Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$108.50
-1.6%
$107.84
$95.49
$148.06
$6.69B0.33833,690 shs478,127 shs
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$8.59
-1.9%
$9.99
$6.48
$22.79
$1.60B0.55135,644 shs441,266 shs
Perrigo Company plc stock logo
PRGO
Perrigo
$26.66
-2.2%
$26.02
$23.14
$30.93
$3.67B0.461.48 million shs1.30 million shs
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$32.03
-2.3%
$32.02
$25.53
$40.28
$1.79B0.71480,475 shs590,662 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
-1.62%-2.37%+1.79%-21.35%-2.27%
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-1.94%-14.01%-19.91%-36.14%-55.61%
Perrigo Company plc stock logo
PRGO
Perrigo
-2.06%+1.84%+2.66%-2.20%-4.24%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
-2.26%-3.38%+1.55%+2.46%+18.28%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
4.9633 of 5 stars
4.52.00.04.03.33.33.1
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
4.2016 of 5 stars
3.54.00.04.22.22.50.0
Perrigo Company plc stock logo
PRGO
Perrigo
4.5449 of 5 stars
2.13.04.23.52.31.72.5
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
2.2116 of 5 stars
2.21.00.04.12.60.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
2.92
Moderate Buy$184.0069.59% Upside
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
3.00
Buy$67.50685.80% Upside
Perrigo Company plc stock logo
PRGO
Perrigo
2.25
Hold$33.0023.78% Upside
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
2.33
Hold$36.0012.39% Upside

Current Analyst Ratings Breakdown

Latest SUPN, JAZZ, PRGO, and NKTR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$202.00
6/3/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$202.00
5/12/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
5/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$182.00 ➝ $172.00
5/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$167.00 ➝ $155.00
5/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$176.00 ➝ $147.00
5/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$183.00 ➝ $166.00
5/7/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$200.00 ➝ $200.00
4/11/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$15.00 ➝ $30.00
4/10/2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$210.00 ➝ $210.00
3/14/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$90.00
(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$4.06B1.65$22.10 per share4.91$59.36 per share1.83
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$87.25M18.32N/AN/A$0.69 per share12.45
Perrigo Company plc stock logo
PRGO
Perrigo
$4.34B0.85$5.57 per share4.79$35.19 per share0.76
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$668.00M2.68$1.47 per share21.83$16.87 per share1.90
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$414.83M$7.5015.285.801.0411.60%29.30%9.72%7/30/2025 (Estimated)
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$276.06M-$0.64N/AN/AN/A-180.70%-173.28%-46.31%8/6/2025 (Estimated)
Perrigo Company plc stock logo
PRGO
Perrigo
-$12.70M-$1.31N/A8.71N/A-3.64%7.38%3.18%8/1/2025 (Estimated)
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$1.32M$1.1129.9322.24N/A9.16%7.79%5.67%8/5/2025 (Estimated)

Latest SUPN, JAZZ, PRGO, and NKTR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$2.70-$3.30-$0.60-$0.24$15.61 million$10.46 million
5/7/2025Q1 2025
Perrigo Company plc stock logo
PRGO
Perrigo
$0.56$0.60+$0.04-$0.05$1.09 billion$1.04 billion
5/6/2025Q1 2025
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
$4.65$1.68-$2.97-$1.52$984.16 million$897.84 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
N/AN/AN/AN/AN/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
$1.164.35%N/AN/A 23 Years
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/AN/AN/AN/AN/A

Latest SUPN, JAZZ, PRGO, and NKTR Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2025
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.294.55%5/30/20255/30/20256/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
1.46
4.26
3.74
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/A
4.24
4.24
Perrigo Company plc stock logo
PRGO
Perrigo
0.94
2.56
1.77
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/A
2.20
1.98

Institutional Ownership

CompanyInstitutional Ownership
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
89.14%
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
75.88%
Perrigo Company plc stock logo
PRGO
Perrigo
95.91%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
4.20%
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
5.25%
Perrigo Company plc stock logo
PRGO
Perrigo
0.70%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
8.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Jazz Pharmaceuticals plc stock logo
JAZZ
Jazz Pharmaceuticals
3,20061.65 million57.92 millionOptionable
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
220186.10 million177.62 millionOptionable
Perrigo Company plc stock logo
PRGO
Perrigo
8,900137.48 million135.47 millionOptionable
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
58055.99 million50.08 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Jazz Pharmaceuticals stock logo

Jazz Pharmaceuticals NASDAQ:JAZZ

$108.50 -1.79 (-1.62%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$104.58 -3.92 (-3.61%)
As of 06/13/2025 07:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Nektar Therapeutics stock logo

Nektar Therapeutics NASDAQ:NKTR

$8.59 -0.17 (-1.94%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$8.66 +0.07 (+0.87%)
As of 06/13/2025 07:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Perrigo stock logo

Perrigo NYSE:PRGO

$26.66 -0.59 (-2.17%)
Closing price 06/13/2025 03:59 PM Eastern
Extended Trading
$26.80 +0.14 (+0.51%)
As of 06/13/2025 06:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Supernus Pharmaceuticals stock logo

Supernus Pharmaceuticals NASDAQ:SUPN

$32.03 -0.74 (-2.26%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$31.80 -0.23 (-0.70%)
As of 06/13/2025 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.